(VIANEWS) – Shares of NICOX (CAC 40: COX.PA) fell by a staggering 17.14% in 5 sessions from €0.7 to €0.58 at 11:06 EST on Tuesday, after five sequential sessions in a row of losses. CAC 40 is sliding 0.63% to €7,525.80, following the last session’s downward trend.
NICOX’s last close was €0.58, 72.49% below its 52-week high of €2.09.
About NICOX
Nicox S.A. operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve ocular health. Its lead product candidate is NCX 470, a novel nitric oxide-donating prostaglandin analog for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in phase 3 clinical trial. The company is also developing NCX 4251, a proprietary formulation of fluticasone for acute exacerbations of blepharitis that is in a Phase 2b clinical trial for the treatment of acute exacerbations of blepharitis; and NCX 1728.It offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis. The company was founded in 1996 and is headquartered in Valbonne, France.
Earnings Per Share
As for profitability, NICOX has a trailing twelve months EPS of €-1.15.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -43.38%.
More news about NICOX (COX.PA).
